Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Decrease in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 12,700 shares, a decrease of 13.0% from the January 15th total of 14,600 shares. Based on an average daily volume of 69,100 shares, the days-to-cover ratio is currently 0.2 days.

Global X Genomics & Biotechnology ETF Stock Up 1.0 %

GNOM traded up $0.10 during trading hours on Tuesday, hitting $10.01. 60,775 shares of the company’s stock were exchanged, compared to its average volume of 62,622. Global X Genomics & Biotechnology ETF has a 1-year low of $9.40 and a 1-year high of $12.53. The stock’s 50-day moving average is $9.96 and its two-hundred day moving average is $10.56. The stock has a market cap of $69.77 million, a price-to-earnings ratio of -4.28 and a beta of 1.03.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. acquired a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $50,000. Oxinas Partners Wealth Management LLC acquired a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $103,000. Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $104,000. Sei Investments Co. acquired a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $114,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 11.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock worth $122,000 after purchasing an additional 1,265 shares during the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.